生物股份:再次捐贈1008萬元的新型冠狀病毒核酸檢測試劑盒
格隆匯2月10日丨生物股份(600201.SH)公佈,自國內新型冠狀病毒感染的肺炎疫情發生以來,公司董事會及管理層高度關注疫情發展,在做好疫情防控工作及自身經營管理的同時,積極響應國家號召,切實履行上市公司社會責任。
公司先期已向內蒙古醫科大學附屬醫院等單位捐贈價值30多萬元醫用口罩、防護服、護目鏡等防疫物資,並於2020年2月8日再次向內蒙古自治區紅十字會捐贈價值1008萬元的新型冠狀病毒(2019-nCoV)核酸檢測試劑盒,用於支持新型冠狀病毒感染肺炎疫情的防控救治工作。目前,上述檢測試劑盒已全部送達指定防疫單位內蒙古自治區綜合疾病預防控制中心。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.